Dutch researchers argued in Nature Medicine that whole-genome sequencing (WGS) should be incorporated into routine cancer care, using real-world data from 888 patients treated at the Netherlands Cancer Institute in Amsterdam. The analysis reported that 73% of patients had at least one clinically actionable biomarker, and WGS produced clinically relevant outputs—including targeted biomarkers, pathogenic germline variants, or diagnostic clarification—in 41%. The team compared WGS to common next-generation sequencing panel strategies, including Thermo Fisher’s 50-gene AmpliSeq Cancer Hotspot panel and a broader 523-gene panel (Illumina TruSight Oncology 500). The study frames the question as both clinical utility and operational cost across a whole oncology population. The findings land as WGS remains non-standard in many settings, where clinicians often choose smaller panels based on expected mutation spectra. It also builds on earlier signals from initiatives such as the UK’s 100,000 Genomes project, where actionable mutation yields varied substantially by tumor type.